IP Library Granted Patent US 6,947,845
Granted Patent B2
US 6,947,845 · App. 10/211,931 · Granted Sep 20, 2005

Method of identifying molecules that bind to the large ribosomal subunit

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,947,845
App. No.
10/211,931
Granted
Sep 20, 2005
Kind
B2
Abstract

The invention provides methods for producing high resolution crystals of ribosomes and ribosomal subunits as well as crystals produced by such methods. The invention also provides high resolution structures of ribosomal subunits either alone or in combination with protein synthesis inhibitors. The invention provides methods for identifying ribosome-related ligands and methods for designing ligands with specific ribosome-binding properties as well as ligands that may act as protein synthesis inhibitors. Thus, the methods and compositions of the invention may be used to produce ligands that are designed to specifically kill or inhibit the growth of any target organism.

Claims (22)

1. A method of identifying a molecule that binds to a large ribosomal subunit, the method comprising the steps of:

(a) providing a molecular model comprising one or more target regions selected from the group consisting of at least a portion of (i) an anisomycin binding site, (ii) an azithromycin binding site, (iii) a blasticidin binding site, (iv) a carbomycin A binding site, (v) an erythromycin binding site, (vi) a linezolid binding site, (vii) a sparsomycin binding site, (viii) a spiramycin binding site, (ix) a tylosin binding site, and (x) a virginiamycin M binding site, wherein the molecular model is made;

(1) from the atomic co-ordinates for the Haloarcula marismortui large ribosomal subunit found on Disk 1 under file names ANISOMYCIN.PDB, azithromycin.pdb, BLASTICIDIN.PDB, CARBOMYCIN.PDB, erythromycin.pdb, linezolid.pdb, SPARSOMYCIN.PDB, SPIRAMYCIN.PDB, TYLOSIN.PDB, or VIRGINAMYCIN.PDB, or found on Disk 1, under FOLDERB, under file names ANISOMYC.PDB, BLASTICI.PDB, CARBOMYC.PDB, SPARSOMY.PDB, SPIRAMYC.PDB, TYLOSIN.PDB, VIRGINIA.PDB, or found on Disk 1, under FOLDERC, under file names AZITHROM.PDB, or LINEZOLI.PDB, or

(2) from atomic co-ordinates derived by molecular modeling using the atomic coordinates for the Haloarcula marismortui large ribosomal subunit found on Disk 1 under file names ANISOMYCIN.PDB. azithromycin.pdb, BLASTICIDIN. PDB, CARBOMYCIN.PDB. erythromycin.pdb, linezolid.pdb, SPARSOMYCIN.PDB, SPIRAMYCIN.PDB, TYLOSIN.PDB, or VIRGINAMYCIN.PDB, or found on Disk 1, under FOLDERB, under file names ANISOMYC.PDB, BLASTICI.PDB, CARBOMYC.PDB, SPARSOMY.PDB, SPIRAMYC.PDB, TYLOSIN.PDB, VIRGINIA.PDB, or found on Disk 1, under FOLDERC, under file names AZITHROM.PDB, or LINEZOLI.PDB;

(b) using the molecular model to identify a candidate molecule that can bind to the molecular model; and

(c) producing the candidate molecule identified in step (b).

2. The method of claim 1 comprising the additional step of determining whether the candidate molecule produced in step (c) modulates ribosomal activity.

3. The method of claim 2 comprising the additional step of repeating steps (a) through (c) to identify and produce a modified candidate molecule having higher binding specificity, higher binding affinity or higher potency relative to the candidate molecule.

4. The method of claims 3 comprising the additional step of determining whether the modified candidate molecule modulates ribosomal activity.

5. The method of claim 4 comprising the additional step of, after determining whether the modified molecule modulates the ribosomal activity, producing a larger quantity of the modified candidate molecule which modulates ribosomal activity.

6. The method of claim 1 , wherein in step (a)(2) the molecular model is derived from the atomic co-ordinates by homology modeling.

7. The method of claim 1 , wherein in step (a)(2) the molecular model is derived from the atomic co-ordinates by molecular replacement.

8. The method of claim 1 , wherein the atomic co-ordinates are found on Disk 1 under file name ANISOMYCIN.PDB, or on Disk 1, under FOLDERB, under file name ANISOMYC.PDB.

9. The method of claim 1 , wherein the atomic co-ordinates are found on Disk 1 under file name azithromycin.pdb or on Disk 1, under FOLDERC, under file name AZITHROM.PDB.

10. The method of claim 1 , wherein the atomic co-ordinates are found on Disk 1 under file name BLASTICIDIN.PDB or on Disk 1, under FOLDERB, under file name BLASTICI.PDB.

11. The method of claim 1 , wherein the atomic co-ordinates are found on Disk 1 under file name CARBOMYCIN.PDB or on Disk 1, under FOLDERB, under file name CARBOMYC.PDB.

12. The method of claim 1 , wherein the atomic co-ordinates are found on Disk 1 under file name erythromycin.pdb.

13. The method of claim 1 , wherein the atomic co-ordinates are found on Disk 1 under file name linezolid.pdb or on Disk 1, under FOLDERC, under file name LINEZOLI.PDB.

14. The method of claim 1 , wherein the atomic co-ordinates are found on Disk 1 under file name SPARSOMYCIN.PDB, or on Disk 1, under FOLDERB, under file name SPARSOMY.PDB.

15. The method of claim 1 , wherein the atomic co-ordinates are found on Disk 1 under file name SPIRAMYCIN.PDB or on Disk 1, under FOLDERB, under file name SPIRAMYC.PDB.

16. The method of claim 1 , wherein the atomic co-ordinates are found on Disk 1 under file name TYLOSIN.PDB or on Disk 1, under FOLDERB, under file name TYLOSIN.PDB.

17. The method of claim 1 , wherein the atomic co-ordinates are found on Disk 1 under file name VIRGINIAMYCIN.PDB or on Disk 1, under FOLDERB, under file name VIRGINIA.PDB.

Assignments (9)
MERGER AND CHANGE OF NAME Recorded Aug 30, 2018
From: MELINTA THERAPEUTICS, INC.; MELINTA SUBSIDIARY CORP.
To: MELINTA SUBSIDIARY CORP.
Reel/Frame 046752/0975 →
RELEASE OF SECURITY INTEREST Recorded Jan 5, 2018
From: SUCHARD SA LLC
To: MELINTA SUBSIDIARY CORP. (F/K/A MELINTA THERAPEUTICS, INC.)
Reel/Frame 044547/0939 →
SECURITY INTEREST Recorded Jun 28, 2017
From: MELINTA THERAPEUTICS, INC.
To: SUCHARD SA LLC
Reel/Frame 042854/0753 →
CHANGE OF NAME Recorded Oct 17, 2013
From: RIB-X PHARMACEUTICALS, INC.
To: MELINTA THERAPEUTICS, INC.
Reel/Frame 031432/0123 →
CONFIRMATORY LICENSE Recorded Jun 27, 2008
From: YALE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021158/0388 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2004
From: BAN, NENAD; NISSEN, POUL; HANSEN, JEFFREY L.
To: YALE UNIVERSITY
Reel/Frame 016010/0730 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2003
From: SUTCLIFFE, JOYCE A.; OYELERE, ADEGBOYEGA K.; IPPOLITO, JOSEPH A.
To: RIB-X PHARMACEUTICALS, INC.
Reel/Frame 013950/0301 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2002
From: SUTCLIFFE, JOYCE A.; OYELERE, ADEGBOYEGA; IPPOLITO, JOSEPH A.
To: RIB-X PHAMACEUTICALS, INC.
Reel/Frame 013567/0375 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2002
From: STEIZ, THOMAS A.; MOORE, PETER B.
To: YALE UNIVERSITY
Reel/Frame 013569/0797 →